Devicor Medical Products, a private equity firm and a GTCR company, has completed its previously announced acquisition of the neoprobe gamma detection system products and related assets from Neoprobe of Dublin, Ohio, reports HealthImaging.com.
Financial terms of the agreement included $30 million cash at close plus up to an additional $20 million in royalties based on revenue milestones. The sale was approved by Neoprobe's shareholders on Aug. 15.
Read the full story here.